SecBot SecBot
6-K ·Filed Jun 29, 2026

ASND

Ascendis Pharma A/S
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001193125-26-288414
Notable filing: 6-K
Actionable Insight • Neutral

The warrant exercise is a routine capital event with no material impact on the stock. Monitor upcoming quarterly earnings and pipeline catalysts for directional signals.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$266.72
T+0 close · Jun 29, 2026 · via day close
Latest settled
−16.34%
T+60 · $223.13
Vs SPY
−19.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $266.72entry
  2. T+1 · 5mo ago +0.40%α +0.54% · $267.79
  3. T+5 · 4mo ago +0.45%α −0.15% · $267.92
  4. T+20 · 4mo ago −4.99%α −3.96% · $253.42
  5. T+60 · 8w ago −16.34%α −19.91% · $223.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma reported the closing of a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 ordinary shares at an average cash consideration of approximately $121.57 per share. The company's share capital increased to DKK 66,189,926, and the articles of association were amended accordingly. This is a routine administrative filing with no material impact on the company's operations or financial outlook.

Key Facts

  • 177,267 ordinary shares issued upon exercise of warrants at an average cash consideration of approximately $121.57 per share.
  • Share capital increased to DKK 66,189,926.
  • Articles of association amended to reflect the capital increase.
  • Exercise window closed on June 29, 2026.

Financial Impact

Approximately $21.5 million in cash proceeds from warrant exercises, negligible dilution relative to $16.6B market cap.

share countcash

Risk Factors

  • Minimal dilution from share issuance, but immaterial at current scale.
  • No new business or pipeline updates in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-288414
Document: d22299d6k.htm0001193125-26-288414
Document: 0001193125-26-288414-index-headers.html0001193125-26-288414
Document: 0001193125-26-288414-index.html0001193125-26-288414
Document: 0001193125-26-288414.txt0001193125-26-288414

Track record

41 reports on ASND

Performance horizon

14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 25 of 27 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (11h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026